Focus: Obsidian Therapeutics is a publicly traded biotechnology company focused on cell and gene therapies for oncology, headquartered in Cambridge, MA with 51-200 employees. The company is advancing OBX-115, a cell therapy candidate in Phase 1/2 development for advanced melanoma.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Best fit for early-stage cell therapy specialists or operations professionals willing to build infrastructure in a capital-backed but unproven platform.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Obsidian Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Obsidian Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Galera Therapeutics, Inc. (GRTX, GRTXD) (CIK 0001563577) — 8-K
8-K
Parvinder Singh Hyare (NASDAQ: GRTX) discloses 6.6% Galera stake after preferred conversion - Stock Titan
Parvinder Singh Hyare (NASDAQ: GRTX) discloses 6.6% Galera stake after preferred conversion Stock Titan
Galera Therapeutics (GRTX) agrees to merger with Obsidian; S-4 includes prospectus - Stock Titan
Galera Therapeutics (GRTX) agrees to merger with Obsidian; S-4 includes prospectus Stock Titan
Galera Therapeutics (GRTX) merger with Obsidian; OBX-115 posts 67% ORR in 15 patients - Stock Titan
Galera Therapeutics (GRTX) merger with Obsidian; OBX-115 posts 67% ORR in 15 patients Stock Titan
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - BioSpace
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting BioSpace
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - Business Wire
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting Business Wire
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15.
Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case series.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo